About DreaMed Diabetes Ltd
DreaMed Diabetes Ltd is a pioneering health AI company that has been transforming diabetes management since 2014. The company developed endo.digital, the world's first FDA-cleared decision support software for both Type 1 and Type 2 diabetes. The platform uses a smart algorithm to analyze CGM, SMBG, and insulin delivery data to generate personalized insulin treatment recommendations that achieve close to 90% agreement with real-world endocrinologists from leading US health systems. endo.digital is a cloud-based SaaS platform that simplifies end-to-end diabetes management across all care settings including endocrinology, diabetes centers, primary care, internal medicine, remote patient monitoring, and population management. The platform features seamless EMR integration through partnership with Redox, eliminating manual documentation and reducing time per patient visit by up to 9 minutes. Clinical studies have demonstrated statistically significant improvements in A1C and Time in Range. Founded by leading endocrinologists, engineers, and data scientists, DreaMed has achieved five FDA clearances and holds six patents. The company serves healthcare provider organizations across the United States, with over 5,000 active patients on the platform as of 2024. DreaMed operates under stringent quality management systems adhering to ISO 27001, GDPR, HIPAA, and SOC 2 standards.
Mission & Story
Mission
Transforming diabetes management, for everyone – everywhere.
Founding Story
In 2014, a visionary group of leading endocrinologists, engineers, and data scientists identified a critical gap between medical expertise and real-time patient needs — and seized the opportunity to transform diabetes management for everyone, everywhere. The founders developed the first artificial pancreas technology.
Clinical Focus
Medical conditions and clinical areas addressed by DreaMed Diabetes Ltd.
Who It Serves
Milestones & Awards
Recent Milestones
Fifth FDA clearance (K232722) in 2024 enabling broader insulin treatment support. Surpassed 5,000 active patients on endo.digital in 2024. endo.digital released for public use in 2022.
Awards & Recognition
World's first company to receive FDA clearance for a smart algorithm providing personalized diabetes treatment recommendations. Pioneered the first artificial pancreas technology. De Novo FDA classification.
Key Partnerships
Company Details
- Founded
- 2014
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 46 →
Abbott Diabetes Care
Abbott Diabetes Care develops FreeStyle Libre, a world-leading continuous glucose monitoring (CGM) portfolio for diabetes management with advanced analytics and innovation.
Amalgam Rx
Amalgam Rx develops AI-powered digital therapeutics and Software as a Medical Device (SaMD) solutions for chronic disease management. The company partners with life sciences companies, health plans, and providers to deliver regulated digital health applications and EHR-integrated clinical decision support tools.
Arkray
ARKRAY USA manufactures and distributes blood glucose monitoring systems, clinical diagnostic equipment, and oral wellness products. The company serves consumers with diabetes, healthcare professionals, and clinical laboratories with accurate, affordable diagnostic solutions.
BeatO
BeatO is a digital health platform specializing in diabetes management and weight loss solutions. The company offers smart glucose monitoring devices, GLP-1 weight loss programs, and a comprehensive diabetes care program combining connected devices, doctor consultations, and health coaching for over 2 million patients across India.
Brook Health
AI-powered remote patient monitoring and chronic disease management platform for conditions like diabetes, hypertension, and heart disease.
Cadence
Cadence delivers AI-powered remote patient care programs for chronic disease management. The company partners with health systems, payers, and medical groups to provide 24/7 monitoring, medication management, and clinical support for patients with hypertension, heart failure, diabetes, and other chronic conditions.
Cala Health
Cala Health develops the Cala kIQ System, an FDA-cleared wearable device that delivers non-invasive neuromodulation therapy for action hand tremor. The device uses transcutaneous afferent patterned stimulation (TAPS) to provide on-demand tremor relief for people with essential tremor and Parkinson's disease.
Calibrate
Calibrate is a metabolic health company that combines clinician-prescribed GLP-1 medications with 1:1 video coaching and science-backed curriculum to help members achieve sustainable weight loss. Members lose an average of 19% of their body weight achieved over three years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.